Transthyretin Amyloid Cardiomyopathy Clinical Trial
Official title:
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Transthyretin Amyloid (ATTR) Cardiomyopathy
This is a single center, single arm, prospective, 12 week open label pilot trial of the sodium-glucose cotransporter 2 inhibitor (SGLT2i), empagliflozin 10 mg oral daily, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The target population for enrollment will be subjects with ATTR-CM and either non-insulin dependent diabetes mellitus or chronic kidney disease. The primary aim will be to assess the safety and tolerability of empagliflozin 10 mg oral daily in subjects with heart failure secondary to ATTR, which remain unexplored. The accrual target is 15 subjects. Consented subjects will be evaluated for safety and tolerability of study drug, empagliflozin 10 mg oral daily, over a period of 12 weeks. Subjects will undergo a total of 6 study visits: 3 in-person and 3 telephone follow-ups.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underrecognized cause of heart failure among older adults, in which misfolded transthyretin (TTR) proteins build up in the muscle tissue of the heart. In 2018, a drug called tafamidis was proven to stabilize the protein and protect people from further damage, and in 2019, it was approved for use in ATTR-CM by the U.S. Food and Drug Administration (FDA). But while people with ATTR-CM are living longer, they continue to suffer from symptoms of heart failure and cardiorenal syndrome as the disease progresses. Sodium glucose co-transporter inhibitors (SGLT2i) are drugs used to treat diabetes mellitus, heart failure, and chronic kidney disease. They may also reduce systemic inflammation, and affect body composition (fat, lean mass, and total water contents) in patients with heart failure, a condition which also has significant overlap with obesity. No one has explored the safety, tolerability, and clinical effects of SGLT2i in patients with heart failure due to ATTR-CM. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
| Active, not recruiting |
NCT06257485 -
Bronx Transthyretin Amyloid Cardiomyopathy Database
|
||
| Recruiting |
NCT06086353 -
A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India
|
||
| Active, not recruiting |
NCT06321523 -
A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|
||
| Not yet recruiting |
NCT06101108 -
Early Diagnosis of Age-Linked CArdiac TransThyRetin Amyloidosis by Selective Screening in Spinal Stenosis Surgery
|
||
| Completed |
NCT04814186 -
A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|
Phase 4 | |
| Recruiting |
NCT04899180 -
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
|
Early Phase 1 | |
| Recruiting |
NCT05259072 -
carDIo-ttranSSfOrm nucLEar Imaging Study
|
Phase 3 | |
| Recruiting |
NCT06183931 -
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
|
Phase 3 | |
| Recruiting |
NCT06328075 -
Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis
|
||
| Recruiting |
NCT06291805 -
Phenotyping and Characterization of wtATTR-CM (TRACE 1)
|
||
| Terminated |
NCT04424914 -
Global Prevalence of ATTR-CM in Participants With HFpEF
|
N/A | |
| Recruiting |
NCT06194825 -
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
|
Phase 3 | |
| Recruiting |
NCT06372301 -
Dobutamine Stress Echocardiography in LF/LG Aortic Stenosis and Wild-type Transthyretin Amyloid Cardiomyopathy
|
N/A |